4568.T
DAIICHI SANKYO COMPANY,LIMITED
プライム · 医薬品 · 医薬品 · JP
JPY 2,854.50
−0.99%Year over year
Reported trailing growth
- Revenue
- +12.6%
- EBITDA
- —
- EBIT
- -31.0%
- EPS
- -9.7%
- Free cash flow
- +18.8%
- Operating cash flow
- +44.2%
Forward estimates
Based on analyst estimates
- Revenue
- -1.1%
- EBITDA
- —
- EPS
- +11.0%
Three-year CAGR
- Revenue
- +18.4%
- EBITDA
- +17.6%
- EBIT
- +23.9%
- Net income
- +33.5%
- EPS
- +35.1%
- Free cash flow
- +18.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026